The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics
- PMID: 2096008
- DOI: 10.1111/j.1365-2265.1990.tb03910.x
The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics
Abstract
We have investigated the relation between nocturnal insulin requirements and nocturnal growth hormone (GH) release in 26 diabetic adolescents at various puberty stages and have examined the effect of nocturnal GH suppression on pre-breakfast insulin requirement. In all the studies, euglycaemia was maintained overnight using a computer-calculated variable-rate insulin infusion, and 15-min blood samples were collected for GH assay. During initial clamp studies, insulin infusion rates were greater from 0500-0800 h (15.22 +/- 0.95 mU/kg/h, mean +/- SEM) than from 0100-0400 h (12.42 +/- 0.84 mU/kg/h, P less than 0.001). The increase in insulin infusion rate correlated with mean overnight GH concentration (r = 0.68, P less than 0.001), and was maximal at puberty stage 3 in both sexes. In seven of the subjects, a second identical clamp was performed following administration of 100 mg oral pirenzepine. During these studies, mean overnight GH levels were reduced by 11-85%, from 17.6 +/- 1.6 to 7.5 +/- 2.2 mU/l; P less than 0.01. Insulin requirements were not significantly different between the periods 0100-0400 and 0500-0800 h during these studies, and the reduction in pre-breakfast (0500-0800 h) insulin requirement when compared with the baseline studies correlated with the fall in GH secretion (rs = 0.82, P less than 0.01). The dawn increase in insulin requirement in adolescents with IDDM is related to the overnight GH secretion during puberty, and pre-breakfast insulin requirement can be reduced by suppressing nocturnal GH release.
Similar articles
-
The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia.Clin Endocrinol (Oxf). 1993 Jan;38(1):93-100. doi: 10.1111/j.1365-2265.1993.tb00978.x. Clin Endocrinol (Oxf). 1993. PMID: 8435890
-
The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.Clin Endocrinol (Oxf). 1995 Nov;43(5):567-74. doi: 10.1111/j.1365-2265.1995.tb02921.x. Clin Endocrinol (Oxf). 1995. PMID: 8548941
-
Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents.Diabetes Care. 1993 Jul;16(7):1011-8. doi: 10.2337/diacare.16.7.1011. Diabetes Care. 1993. PMID: 8359093
-
Nocturnal blood glucose control in type I diabetes mellitus.Diabetes Care. 1993 Dec;16 Suppl 3:71-89. doi: 10.2337/diacare.16.3.71. Diabetes Care. 1993. PMID: 8299480 Review.
-
Recombinant IGF-I therapy in insulin-dependent diabetes mellitus.Diabetes Metab. 1996 Jul;22(4):257-60. Diabetes Metab. 1996. PMID: 8767172 Review.
Cited by
-
Insulin doses before and one year after pump start: children have a reversed dawn phenomenon.J Diabetes Sci Technol. 2012 May 1;6(3):589-94. doi: 10.1177/193229681200600314. J Diabetes Sci Technol. 2012. PMID: 22768890 Free PMC article.
-
The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus.Diabetologia. 2003 Sep;46(9):1203-10. doi: 10.1007/s00125-003-1175-8. Epub 2003 Jul 24. Diabetologia. 2003. PMID: 12898010 Clinical Trial.
-
Carbohydrate Intake in the Context of Exercise in People with Type 1 Diabetes.Nutrients. 2019 Dec 10;11(12):3017. doi: 10.3390/nu11123017. Nutrients. 2019. PMID: 31835538 Free PMC article. Review.
-
Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.Diabetologia. 1996 Aug;39(8):961-9. doi: 10.1007/BF00403916. Diabetologia. 1996. PMID: 8858219 Clinical Trial.
-
Dual-basal-insulin regimen for the management of dawn phenomenon in children with type 1 diabetes: a retrospective cohort study.Ther Adv Endocrinol Metab. 2023 Dec 25;14:20420188231220130. doi: 10.1177/20420188231220130. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 38152658 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials